Collaborative Research on New Drugs for the Treatment of Tuberculosis and Malaria

Astellas is pursuing collaborative research to discover new drugs for the treatment of tuberculosis and malaria, which are infectious diseases that cause tremendous suffering among people in developing countries.

In 2018 10 million incidences of tuberculosis were observed with 1.5 million* deaths, and more than 200 million incidences of malaria were observed with 405,000 deaths. Both tuberculosis and malaria have led to serious social problems, underscoring the urgent need for innovative drugs to treat these diseases.

Considering these backgrounds, in October 2017, Astellas entered into a new collaborative research agreement with TB Alliance for the exploration of new drugs for the treatment of tuberculosis and a screening collaboration agreement with Medicines for Malaria Venture (MMV) to discover new drugs for malaria. 

Under these agreements, Astellas provides its original library of compounds, while TB Alliance and MMV conduct screenings of the library to discover hit compounds to be used in the research and development of new tuberculosis and malaria drugs, respectively.

These research programs are funded by the Global Health Innovative Technology Fund (“GHIT Fund”).

*Figure includes 0.25 million people infected with HIV.